WO2004018512A3 - Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications - Google Patents

Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications Download PDF

Info

Publication number
WO2004018512A3
WO2004018512A3 PCT/EP2003/009356 EP0309356W WO2004018512A3 WO 2004018512 A3 WO2004018512 A3 WO 2004018512A3 EP 0309356 W EP0309356 W EP 0309356W WO 2004018512 A3 WO2004018512 A3 WO 2004018512A3
Authority
WO
WIPO (PCT)
Prior art keywords
relates
methods
polynucleotide
genes
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/009356
Other languages
French (fr)
Other versions
WO2004018512A2 (en
Inventor
Reinhold Kerb
Hermann Koepsell
Ulrich Brinkmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epidauros Biotechnologie AG
Original Assignee
Epidauros Biotechnologie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidauros Biotechnologie AG filed Critical Epidauros Biotechnologie AG
Priority to EP03792418A priority Critical patent/EP1534747A2/en
Priority to JP2004530253A priority patent/JP2006516182A/en
Priority to US10/525,360 priority patent/US20060122372A1/en
Priority to AU2003264094A priority patent/AU2003264094A1/en
Publication of WO2004018512A2 publication Critical patent/WO2004018512A2/en
Publication of WO2004018512A3 publication Critical patent/WO2004018512A3/en
Anticipated expiration legal-status Critical
Priority to US12/221,241 priority patent/US20090018030A1/en
Priority to US12/221,130 priority patent/US20090061452A1/en
Priority to US12/477,506 priority patent/US20100009366A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.
PCT/EP2003/009356 2002-08-23 2003-08-22 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications Ceased WO2004018512A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP03792418A EP1534747A2 (en) 2002-08-23 2003-08-22 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
JP2004530253A JP2006516182A (en) 2002-08-23 2003-08-22 Polymorphisms in the human gene of OCT1 and its use in diagnostic and therapeutic applications
US10/525,360 US20060122372A1 (en) 2002-08-23 2003-08-22 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
AU2003264094A AU2003264094A1 (en) 2002-08-23 2003-08-22 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
US12/221,241 US20090018030A1 (en) 2002-08-23 2008-07-30 Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications
US12/221,130 US20090061452A1 (en) 2002-08-23 2008-07-30 Polymorphisms in the human genes for OCT 1 and their use in diagnostic and therapeutic applications
US12/477,506 US20100009366A1 (en) 2002-08-23 2009-06-03 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018904 2002-08-23
EP02018904.9 2002-08-23

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/221,130 Division US20090061452A1 (en) 2002-08-23 2008-07-30 Polymorphisms in the human genes for OCT 1 and their use in diagnostic and therapeutic applications
US12/221,241 Division US20090018030A1 (en) 2002-08-23 2008-07-30 Polymorphisms in the human genes for OCT1 and their use in diagnostic and therapeutic applications
US12/477,506 Continuation US20100009366A1 (en) 2002-08-23 2009-06-03 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications

Publications (2)

Publication Number Publication Date
WO2004018512A2 WO2004018512A2 (en) 2004-03-04
WO2004018512A3 true WO2004018512A3 (en) 2004-07-01

Family

ID=31896844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/009356 Ceased WO2004018512A2 (en) 2002-08-23 2003-08-22 Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications

Country Status (5)

Country Link
US (4) US20060122372A1 (en)
EP (2) EP1534747A2 (en)
JP (1) JP2006516182A (en)
AU (1) AU2003264094A1 (en)
WO (1) WO2004018512A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264094A1 (en) * 2002-08-23 2004-03-11 Epidauros Biotechnologie Ag Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
WO2005026723A1 (en) * 2003-09-13 2005-03-24 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a1 (slc22a1)
US10611986B1 (en) 2018-03-15 2020-04-07 Earthcare Labs, Llc Cleaning composition comprising a cationic/nonionic mixture

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059142A2 (en) * 2001-01-26 2002-08-01 Epidauros Biotechnologies Ag Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
JP3626187B2 (en) 1993-06-07 2005-03-02 バイカル インコーポレイテッド Plasmid suitable for gene therapy
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
DE4424577A1 (en) * 1994-07-13 1996-01-18 Hoechst Ag Transporter protein for cationic xenobiotic(s) and pharmaceuticals, and related DNA and transformed cells
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US20010049586A1 (en) * 2000-04-05 2001-12-06 Roses Allen David Iterative analysis of non-responding population in the design of pharmacogenetic studies
AU2003264094A1 (en) * 2002-08-23 2004-03-11 Epidauros Biotechnologie Ag Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059142A2 (en) * 2001-01-26 2002-08-01 Epidauros Biotechnologies Ag Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 10 September 2001 (2001-09-10), WATERSON: "Homo sapiens chromosome UNK clone RP11-112b7", XP002267878, Database accession no. ac093630 *
DATABASE EMBL [online] 23 March 1998 (1998-03-23), SULTON ET AL.: "Homo sapiens PAC clone RP-5-844F9 from 7, complete sequence", XP002267877, Database accession no. ac004453 *
DATABASE EMBL [online] 6 February 2001 (2001-02-06), BIRREN ET AL.: "Mus musculus chromosome 12 clone RP23-283B7 map 12", XP002267879, Database accession no. ac109228 *
DRESSER M J LEABMAN M K GIACOMINI K M: "Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 90, no. 4, April 2001 (2001-04-01), pages 397 - 421, XP002959943, ISSN: 0022-3549 *
KERB REINHOLD ET AL: "Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences.", PHARMACOGENETICS, vol. 12, no. 8, November 2002 (2002-11-01), pages 591 - 595, XP009024431, ISSN: 0960-314X *
See also references of EP1534747A2 *
SHU Y ET AL: "Identification and functional characterization of hOCT1 polymorphisms in ethnically diverse populations", CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 71, no. 2, February 2002 (2002-02-01), Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics;Atlanta, Georgia, USA; March 24-27, 2002, pages P73, XP009024430, ISSN: 0009-9236 *
SHU YAN ET AL: "Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. UNITED STATES 13 MAY 2003, vol. 100, no. 10, 13 May 2003 (2003-05-13), pages 5902 - 5907, XP002267876, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2003264094A1 (en) 2004-03-11
US20100009366A1 (en) 2010-01-14
WO2004018512A2 (en) 2004-03-04
EP2319866A3 (en) 2012-08-29
JP2006516182A (en) 2006-06-29
US20060122372A1 (en) 2006-06-08
EP2319866A2 (en) 2011-05-11
US20090018030A1 (en) 2009-01-15
US20090061452A1 (en) 2009-03-05
EP1534747A2 (en) 2005-06-01

Similar Documents

Publication Publication Date Title
RU2360923C2 (en) Novel ligand of cytokine receptor zcytor17
WO2005108615A3 (en) Nucleic-acid programmable protein arrays
JP2006515749A5 (en)
JP2011509073A5 (en)
AU2002224967A1 (en) Identification of genetic determinants of polymorphic cyp3a5 expression
WO2001055308A3 (en) Nucleic acids, proteins, and antibodies
JP2009519002A5 (en)
HU0400904D0 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
WO2002061131A3 (en) Human single nucleotide polymorphisms
WO2002099099A3 (en) Polymorphisms in the human gene for cytochrome p450 polypeptide 2c8 and their use in diagnostic and therapeutic applications
WO2003052076A3 (en) Identification of essential genes of cryptococcus neoformans and methods of use
WO2003063773A3 (en) Differentially-regulated prostate cancer genes
WO2003097873A3 (en) Polymorphisms in the human gene for htr3b and their use in diagnostic and therapeutic applications
WO2004018512A3 (en) Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
WO2002059142A3 (en) Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications
WO2003014387A3 (en) Polymorphisms in the human gene for cyp1a2 and their use in diagnostic and therapeutic applications
RU2008102731A (en) NEW BIOLOGICAL SUBSTANCE NESFATIN, MATTERS RELATED TO IT AND THEIR APPLICATION
CN110225973B (en) Protein Screening and Detection Methods
WO2002024747A3 (en) Polymorphisms in human genes of cardiovascular regulators and their use in diagnostic and therapeutic applications
WO2005067648A3 (en) Multiplex spatial profiling of gene expression
EP1655382A3 (en) Colon specific gene and protein
CN106460060A (en) HNF4G-RSPO2 fusion gene and use thereof in treatment of cancer
DE69734199D1 (en) HUMAN NETRIN-1
WO2003000727A3 (en) Atopy
WO2003102159A3 (en) Novel proteins and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004530253

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2003792418

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003792418

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003792418

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006122372

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10525360

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10525360

Country of ref document: US